Phosphoinositide 3-Kinases
From Proteopedia
(Difference between revisions)
Line 37: | Line 37: | ||
</StructureSection> | </StructureSection> | ||
- | == 3D Structures of PI3K== | ||
- | Updated on {{REVISIONDAY2}}-{{MONTHNAME|{{REVISIONMONTH}}}}-{{REVISIONYEAR}} | ||
- | {{#tree:id=OrganizedByTopic|openlevels=0| | ||
- | *Class I p85α | ||
- | |||
- | **[[2iug]], [[2iuh]], [[2iui]] – hPI3KI p85α N-terminal+ peptides - human<br /> | ||
- | **[[1h9o]] – hPI3KI p85α C-terminal + PDGFR peptide<br /> | ||
- | **[[2vly]] - hPI3KI p85α+ABD<br /> | ||
- | **[[1pic]] - hPI3K p85α subunit SH2 domain + β-platelet-derived growth factor receptor peptide – NMR<br /> | ||
- | **[[3i5s]], [[3i5r]], [[1pht]] - hPI3KI p85α SH3 domain<br /> | ||
- | **[[1pks]], [[1pkt]] - hPI3KI p85α SH3 domain – NMR<br /> | ||
- | **[[1pbw]], [[2xs6]] - hPI3K p85α subunit RhoGAP domain <br /> | ||
- | **[[1bfi]], [[1bfj]], [[2pna]], [[2pnb]] - bPI3KI p85α SH2 domain – bovine – NMR<br /> | ||
- | **[[1oo3]] - bPI3KI p85α SH2 domain (mutant) – NMR<br /> | ||
- | **[[1oo4]] - bPI3KI p85α SH2 domain (mutant) + PDGFR peptide – NMR<br /> | ||
- | **[[1qad]] - bPI3KI p85α SH2 domain<br /> | ||
- | **[[1pnj]], [[2pni]] – bPI3K p85α subunit SH3 domain – NMR<br /> | ||
- | **[[1fu5]], [[1fu6]] – PI3KI p85α + peptides – NMR – rat<br /> | ||
- | |||
- | *Class I p85β | ||
- | |||
- | **[[3mtt]], [[3o5z]] – hPI3KI p85β <br /> | ||
- | **[[2kt1]] - hPI3KI p85β SH3 domain<br /> | ||
- | **[[3l4q]] – bPI3KI p85β + influenza NS1 protein <br /> | ||
- | |||
- | *'''Class II''' | ||
- | |||
- | **[[2wwe]] – hPI3KIIγ PHOX homology domain<br /> | ||
- | **[[2ar5]], [[2iwl]], [[2rea]], [[2red]], [[6bub]]– hPI3KII PX domain<br /> | ||
- | **[[2b3r]], [[6btz]], [[6bty]] - hPI3KII C2 domain<br /> | ||
- | **[[6bu0]] - hPI3KII C2 domain + IP6<br /> | ||
- | |||
- | *'''Class III''' | ||
- | |||
- | **[[3ihy]] – hPI3KIII p100<br /> | ||
- | **[[3ls8]], [[5enn]], [[5anl]] – hPI3KIII p100 + inhibitor <br /> | ||
- | **[[6i3u]] – hPI3KIII p100 (mutant) + inhibitor <br /> | ||
- | **[[2x6f]], [[2x6h]], [[2x6j]], [[2x6k]], [[2x6i]] – PI3KIII + inhibitors – ''Drosophila melanogaster''<br /> | ||
- | |||
- | *'''Type I PI3K (Phosphatidylinositol-4,5-bisphosphate 3-kinase)''' | ||
- | |||
- | *Type I PI3K p110α+ p85α | ||
- | |||
- | **[[3hhm]] - hTI-PI3K p110α + p85α SH2 domain + wortmannin<br /> | ||
- | **[[3hiz]], [[4jps]] - hTI-PI3K p110α (mutant) + p85α <br /> | ||
- | **[[2rd0]], [[4l1b]], [[6nct]] - hTI-PI3K p110α + p85α<br /> | ||
- | **[[5sxk]], [[5sx8]], [[5sx9]], [[5sxa]], [[5sxb]], [[5sxc]], [[5sxd]], [[5sxe]], [[5sxf]], [[5sxi]], [[5sxj]], [[5sw8]], [[5swg]], [[5swo]], [[5swp]], [[5swr]], [[5swt]], [[5dxh]], [[5xgj]], [[5xgi]]], [[5xgh]] - hTI-PI3K p110α + p85α + inhibitor<br /> | ||
- | **[[5ul1]], [[5ukj]], [[5itd]], [[5fi4]], [[4zop]] - hTI-PI3K p110α (mutant) + p85α + inhibitor<br /> | ||
- | **[[5uk8]] - hTI-PI3K p110α (mutant) + p85α (mutant) + inhibitor<br /> | ||
- | **[[4ovu]] - hTI-PI3K p110α + p85α SH2 domain<br /> | ||
- | **[[4ovv]] - hTI-PI3K p110α + p85α SH2 domain + phosphatidylinositol-4,5-bisphosphate <br /> | ||
- | **[[4l23]], [[4l2y]] - hTI-PI3K p110α + p85α + inhibitor<br /> | ||
- | **[[4waf]] - hTI-PI3K p110α (mutant) + p85α (mutant) + inhibitor<br /> | ||
- | **[[2v1y]] - bTI-PI3K p110α +h-p85α<br /> | ||
- | |||
- | *Type I PI3K p110α | ||
- | |||
- | **[[4tuu]], [[4tv3]] - hTI-PI3K p110α<br /> | ||
- | **[[2enq]] - hTI-PI3K p110α C2 domain<br /> | ||
- | **[[3zim]], [[4a55]], [[4oys]], [[4ph4]], [[4uwf]], [[4uwg]], [[4uwh]], [[4uwk]], [[4uwl]], [[5ubr]], [[5dxt]], [[4ykn]], [[6pys]], [[6oac]], [[6gvi]], [[6gvh]], [[6gvg]], [[6gvf]] - hTI-PI3K p110α + inhibitor<br /> | ||
- | |||
- | *Type I PI3K p110β | ||
- | |||
- | **[[2y3a]] - hTI-PI3K p110β + p85β + drug<br /> | ||
- | **[[4bfr]] - TI-PI3K p110β + inhibitor – mouse<br /> | ||
- | |||
- | *Type I PI3K p110γ | ||
- | |||
- | **[[3lj3]], [[5oq4]], [[6c1s]] – hTI-PI3K p110γ + pyridine derivative inhibitor <br /> | ||
- | **[[3l54]] – hTI-PI3K p110γ + quinoline derivative <br /> | ||
- | **[[3l08]] – hTI-PI3K p110γ + GSK2126458 <br /> | ||
- | **[[3ibe]]– hTI-PI3K p110γ + pyrazolopyrimidine <br /> | ||
- | **[[3ene]], [[2v4l]], [[2a4z]], [[2a5u]], [[1e7u]], [[1e7v]], [[1e8w]], [[1e8y]], [[1e8z]], [[1e90]], [[1e8x]], [[3tls]], [[3apc]], [[3apd]], [[3apf]], [[3s2a]], [[3r7q]], [[3r7r]], [[3p2b]], [[3mjw]], [[3nzs]], [[3nzu]], [[3qaq]], [[3qar]], [[3zvv]], [[3zw3]], [[3sd5]], [[3t8m]], [[3tl5]], [[4anu]], [[4anv]], [[4anw]], [[4anx]], [[4aof]], [[4dk5]], [[4f1s]], [[4fa6]], [[4fad]], [[4fhj]], [[4fhk]], [[4fjy]], [[4fjz]], [[4flh]], [[4ful]], [[4g11]], [[4gb9]], [[4hle]], [[4hvb]], [[4j6i]], [[4ps3]], [[4ps7]], [[4ps8]], [[4urk]], [[4wwn]], [[4wwo]], [[4wwp]], [[5t23]], [[5kae]], [[5jhb]], [[5jha]], [[5g55]], [[5g2n]], [[5eds]], [[4xz4]], [[4xx5]], [[6gq7]], [[6fh5]] – hTI-PI3K p110γ + inhibitor <br /> | ||
- | **[[3tjp]], [[4ezj]], [[4ezk]], [[4ezl]], [[4kz0]], [[4kzc]] - hTI-PI3K p110γ (mutant) + inhibitor<br /> | ||
- | **[[3dpd]], [[6aud]] – hTI-PI3K p110γ + oxazines inhibitor <br /> | ||
- | **[[3dbs]] – hTI-PI3K p110γ + GDC0941 <br /> | ||
- | **[[3csf]], [[3cst]] – hTI-PI3K p110γ + organourethenium inhibitor <br /> | ||
- | **[[2chw]], [[2chx]], [[2chz]] – hTI-PI3K p110γ + PIK-39 inhibitor<br /> | ||
- | **[[3oaw]], [[3ml9]], [[3ml8]], [[3l17]], [[3l16]], [[3l13]], [[3pre]], [[3prz]], [[3ps6]], [[3qjz]], [[3qk0]] – hTI-PI3K p110γ + PI3K/mTOR dual inhibitor<br /> | ||
- | **[[1he8]] - hTI-PI3K p110γ + transforming protein P21/H-RAS-1 effector domain<br /> | ||
- | |||
- | *Type I PI3K p110δ | ||
- | |||
- | **[[2x38]] – hTI-PI3K p110δ + IC87114 <br /> | ||
- | **[[2wxf]], [[2wxg]], [[2wxh]], [[2wxi]], [[2wxj]], [[2wxk]], [[2wxl]], [[2wxm]], [[2wxn]], [[2wxo]], [[2wxp]], [[2wxq]], [[2wxr]], [[4ajw]] – hTI-PI3K p110δ + inhibitor<br /> | ||
- | |||
- | }} | ||
==Additional Resources== | ==Additional Resources== | ||
* See: [[Cancer]] For Additional Proteins involved in the disease. <br /> | * See: [[Cancer]] For Additional Proteins involved in the disease. <br /> |
Revision as of 09:24, 18 November 2019
This page, as it appeared on November 15, 2010, was featured in this article in the journal Biochemistry and Molecular Biology Education.
|
Additional Resources
- See: Cancer For Additional Proteins involved in the disease.
- See: Oncogenes for Additional examples of oncogenes and tumor suppressor genes.
References
- ↑ Djordjevic S, Driscoll PC. Structural insight into substrate specificity and regulatory mechanisms of phosphoinositide 3-kinases. Trends Biochem Sci. 2002 Aug;27(8):426-32. PMID:12151228
- ↑ 2.0 2.1 2.2 Wymann MP, Pirola L. Structure and function of phosphoinositide 3-kinases. Biochim Biophys Acta. 1998 Dec 8;1436(1-2):127-50. PMID:9838078
- ↑ Sasaki T, Irie-Sasaki J, Horie Y, Bachmaier K, Fata JE, Li M, Suzuki A, Bouchard D, Ho A, Redston M, Gallinger S, Khokha R, Mak TW, Hawkins PT, Stephens L, Scherer SW, Tsao M, Penninger JM. Colorectal carcinomas in mice lacking the catalytic subunit of PI(3)Kgamma. Nature. 2000 Aug 24;406(6798):897-902. PMID:10972292 doi:10.1038/35022585
- ↑ Bi L, Okabe I, Bernard DJ, Wynshaw-Boris A, Nussbaum RL. Proliferative defect and embryonic lethality in mice homozygous for a deletion in the p110alpha subunit of phosphoinositide 3-kinase. J Biol Chem. 1999 Apr 16;274(16):10963-8. PMID:10196176
- ↑ Miled N, Yan Y, Hon WC, Perisic O, Zvelebil M, Inbar Y, Schneidman-Duhovny D, Wolfson HJ, Backer JM, Williams RL. Mechanism of two classes of cancer mutations in the phosphoinositide 3-kinase catalytic subunit. Science. 2007 Jul 13;317(5835):239-42. PMID:17626883 doi:317/5835/239
- ↑ Stephens LR, Hughes KT, Irvine RF. Pathway of phosphatidylinositol(3,4,5)-trisphosphate synthesis in activated neutrophils. Nature. 1991 May 2;351(6321):33-9. PMID:1851250 doi:http://dx.doi.org/10.1038/351033a0
- ↑ Hoedemaeker FJ, Siegal G, Roe SM, Driscoll PC, Abrahams JP. Crystal structure of the C-terminal SH2 domain of the p85alpha regulatory subunit of phosphoinositide 3-kinase: an SH2 domain mimicking its own substrate. J Mol Biol. 1999 Oct 1;292(4):763-70. PMID:10525402 doi:http://dx.doi.org/10.1006/jmbi.1999.3111
- ↑ Harris SJ, Foster JG, Ward SG. PI3K isoforms as drug targets in inflammatory diseases: lessons from pharmacological and genetic strategies. Curr Opin Investig Drugs. 2009 Nov;10(11):1151-62. PMID:19876783
Proteopedia Page Contributors and Editors (what is this?)
David Canner, Michal Harel, Joel L. Sussman, Jaime Prilusky, Hannah Campbell, Alexander Berchansky, Angel Herraez